!ID 0000001
!v001!176184
!v002!88
!ID 0000002
!v001!176204
!v002!108
!ID 0000003
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!5
!v701!1
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="right"><b><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">ARTIGOS    ORIGINAIS</font></b></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000004
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!6
!v701!2
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000005
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!7
!v701!3
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="4"><b><a name="top10"></a>Preval&ecirc;ncia    e fatores associados &agrave; hepatite C em pacientes de hemodi&aacute;lise</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000006
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!8
!v701!4
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000007
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!9
!v701!5
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><b><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3">Prevalence    and associated factors to hepatitis C in hemodialysis patients in Brazil</font></b></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000008
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!10
!v701!6
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000009
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!11
!v701!7
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000010
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!12
!v701!8
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>Maria    Teresa Gon&ccedil;alves de Medeiros<sup>I</sup>; Jos&eacute; Milton de Castro    Lima<sup>I</sup>; Jos&eacute; Wellington de Oliveira Lima<sup>II</sup>; Henry    de Holanda Campos<sup>I</sup>; Marta Maria das Chagas Medeiros<sup>I</sup>;    Jo&atilde;o Macedo Coelho Filho<sup>I</sup></b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000011
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!13
!v701!9
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><sup>I</sup>Departamento    de Medicina Cl&iacute;nica da Faculdade de Medicina da Universidade Federal    do Cear&aacute;. Fortaleza, CE, Brasil    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000012
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!14
!v701!10
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   <sup>II</sup>Departamento de Sa&uacute;de P&uacute;blica da Universidade Estadual    do Cear&aacute;. Fortaleza, CE, Brasil</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000013
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!15
!v701!11
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back10">Endere&ccedil;o    para correspond&ecirc;ncia</a></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000014
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!16
!v701!12
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000015
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!17
!v701!13
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p> <hr size="1" noshade>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000016
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!18
!v701!14
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000017
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!19
!v701!15
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>OBJETIVO:</b>    A preval&ecirc;ncia da infec&ccedil;&atilde;o pelo v&iacute;rus da hepatite    C (VHC) &eacute; maior em pacientes submetidos &agrave; hemodi&aacute;lise que    na popula&ccedil;&atilde;o em geral, possivelmente refletindo maior exposi&ccedil;&atilde;o    a situa&ccedil;&otilde;es de risco. O estudo realizado teve por objetivo determinar    a preval&ecirc;ncia de anticorpos anti-VHC em pacientes em hemodi&aacute;lise    e identificar fatores relacionados &agrave;s cl&iacute;nicas e aos pacientes,    associados &agrave; transmiss&atilde;o do VHC.    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000018
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!20
!v701!16
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>M&Eacute;TODOS:</b></font><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">    Realizou-se estudo transversal em 752 pacientes em hemodi&aacute;lise em todas    as 12 cl&iacute;nicas de Fortaleza, Cear&aacute;. Eles foram testados com anticorpos    anti-VHC por ELISA de terceira gera&ccedil;&atilde;o. Foram entrevistados 663    pacientes quanto a aspectos sociodemogr&aacute;ficos, cl&iacute;nicos e epidemiol&oacute;gicos.    Fatores nosocomiais foram investigados utilizando-se question&aacute;rio espec&iacute;fico.    Para a an&aacute;lise estat&iacute;stica foram aplicados o teste <i>t</i> de    <i>Student</i>, o <i>odds ratio</i> e a regress&atilde;o log&iacute;stica univariada    e multivariada.    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000019
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!21
!v701!17
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   <b>RESULTADOS:</b> A preval&ecirc;ncia de anti-VHC foi de 52% (390/746; variando    de 6% a 72%). A freq&uuml;&ecirc;ncia de infec&ccedil;&atilde;o foi maior em    pacientes previamente submetidos &agrave; di&aacute;lise peritoneal (OR=1,76;    IC 95% 1,12-2,76) e a transfus&otilde;es de sangue (OR=2,75; IC 95% 1,25-6,03)<i>.</i>    O tempo de hemodi&aacute;lise associou-se com positividade do anti-VHC (OR=1,47;    IC 95% 1,35-1,61). Procedimentos nas cl&iacute;nicas associados &agrave; positividade    do anti-VHC foram preparo pr&eacute;vio de heparina (OR=2,92; IC 95% 1,23-6,92),    falha no uso ou troca de luvas (OR=5,73; IC 95% 1,75-18,72), desinfec&ccedil;&atilde;o    de m&aacute;quinas de di&aacute;lise (OR=2,79; IC 95% 1,57-4,96) e segrega&ccedil;&atilde;o    em sala de di&aacute;lise (OR=0,18; IC 95% 0,05-0,61).    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000020
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!22
!v701!18
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   <b>CONCLUS&Otilde;ES:</b> Os resultados mostraram elevada preval&ecirc;ncia    de anti-VHC em pacientes sob hemodi&aacute;lise e a associa&ccedil;&atilde;o    de fatores de transmiss&atilde;o nosocomial com a infec&ccedil;&atilde;o pelo    VHC.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000021
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!23
!v701!19
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>Descritores:</b>    Hepatite C, epidemiologia. Anticorpos anti-hepatite C. Di&aacute;lise renal.    Preval&ecirc;ncia. Estudos transversais. Fatores de risco. Fatores socioecon&ocirc;micos.    ELISA. Soroconvers&atilde;o.</font></p> <hr size="1" noshade>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000022
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!24
!v701!20
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000023
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!25
!v701!21
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>OBJECTIVE:</b>    The prevalence of hepatitis C virus (HCV) is higher in patients on hemodialysis    than in the general population, probably due to greater exposure to risk situations.    The purposes of the study were to determine anti-HCV antibodies prevalence among    hemodialysis patients and dialysis clinics and patients factors associated with    HCV transmission.    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000024
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!26
!v701!22
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   <b>METHODS:</b> A cross-sectional study was conducted in 752 hemodialysis patients    in all 12 dialysis clinics of Fortaleza, Brazil, and were screened using third    generation ELISA. Sociodemographic, clinical, and epidemiological data of 663    patients were collected through interviews. Nosocomial factors were assessed    using a specific questionnaire tool. Statistical analysis was conducted using    Student's t test, odds ratio and multivariate analysis.    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000025
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!27
!v701!23
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   <b>RESULTS:</b> The prevalence of anti-HCV was 52% (390/746; ranged from 6%    to 72%). The anti-HCV positivity was higher in patients who had previous peritoneal    dialysis (OR=1.76; 95% CI 1.12-2.76) and blood transfusion (OR=2.75; 95% CI    1.25-6.03). Dialysis age has been associated with anti-HCV positivity (OR=1.47;    95% CI 1.35-1.61). Clinics practices associated with anti-HCV positivity were:    previous preparing of heparin (OR=2.92; 95% CI 1.23-6.92), failure in gloves    use or change (OR=5.73; 95% CI 1.75-18.72), unsatisfactory dialysis machine    disinfection (OR=2.79; 95% CI 1.57-4.96), and patient isolation in dialysis    room (OR=0.18; 95% CI 0.05-0.61).    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000026
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!28
!v701!24
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   <b>CONCLUSIONS:</b> The results show high anti-HCV prevalence among hemodialysis    patients and the association of nosocomial factors with new HCV infection cases.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000027
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!29
!v701!25
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>Keywords:</b>    Hepatitis C, epidemiology. Hepatitis C antibodies. Renal dialysis. Prevalence.    Cross-sectional studies. Risk factors. Socioeconomic factors. Enzyme-linked    immunosorbent assay. Seroconversion.</font></p> <hr size="1" noshade>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000028
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!30
!v701!26
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000029
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!31
!v701!27
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000030
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!32
!v701!28
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000031
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!33
!v701!29
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">A preval&ecirc;ncia    de hepatite C &eacute; alta em pacientes submetidos &agrave; hemodi&aacute;lise.<sup>3,5,7,16,18,20</sup>    O principal modo de transmiss&atilde;o &eacute; pelas transfus&otilde;es de    sangue contaminado, mas a via nosocomial tem sido freq&uuml;entemente observada.<sup>16</sup>    Isto tem levado a questionamentos sobre os poss&iacute;veis fatores de risco<sup>11,15</sup>    e a discuss&otilde;es a respeito de medidas profil&aacute;ticas. Alguns autores    defendem a separa&ccedil;&atilde;o dos pacientes com anticorpos contra o v&iacute;rus    da hepatite C (VHC) em uma sala de hemodi&aacute;lise espec&iacute;fica.<sup>17</sup>    Outros advogam que a transmiss&atilde;o nosocomial se deve &agrave; n&atilde;o    observ&acirc;ncia das precau&ccedil;&otilde;es universais.<sup>13</sup> O conhecimento    de fatores relacionados &agrave; hepatite C em pacientes renais cr&ocirc;nicos    &eacute; essencial para o controle dessa infec&ccedil;&atilde;o.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000032
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!34
!v701!30
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Poucos s&atilde;o    os dados dispon&iacute;veis no Brasil sobre a preval&ecirc;ncia e os fatores    associados &agrave; infec&ccedil;&atilde;o pelo VHC nos pacientes em hemodi&aacute;lise,    o que motivou a realiza&ccedil;&atilde;o do presente estudo, cujos objetivos    foram: determinar a preval&ecirc;ncia de anti-VHC em pacientes renais cr&ocirc;nicos    submetidos &agrave; hemodi&aacute;lise e estudar fatores individuais e procedimentos    utilizados nas cl&iacute;nicas de hemodi&aacute;lise potencialmente capazes    de contribuir para a transmiss&atilde;o do v&iacute;rus da hepatite C.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000033
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!35
!v701!31
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000034
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!36
!v701!32
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000035
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!37
!v701!33
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">O delineamento    do estudo foi transversal. Foram avaliados todos os pacientes renais cr&ocirc;nicos    submetidos &agrave; hemodi&aacute;lise em tratamento regular nas 12 cl&iacute;nicas    de hemodi&aacute;lise da cidade de Fortaleza, Cear&aacute;.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000036
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!38
!v701!34
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Todos os    pacientes foram analisados quanto &agrave; presen&ccedil;a do anticorpo para    o v&iacute;rus da hepatite C, para a determina&ccedil;&atilde;o dessa preval&ecirc;ncia    no per&iacute;odo de fevereiro a mar&ccedil;o de 1997.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000037
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!39
!v701!35
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">A observa&ccedil;&atilde;o    dos procedimentos rotineiros das cl&iacute;nicas durante as sess&otilde;es de    hemodi&aacute;lise foi feita de agosto a outubro de 1997.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000038
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!40
!v701!36
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Ap&oacute;s    consentimento das unidades de di&aacute;lise e dos pacientes renais cr&ocirc;nicos    em participar do estudo, foi a estes &uacute;ltimos aplicado um question&aacute;rio    contemplando as seguintes vari&aacute;veis: sexo, idade, estado civil, renda    familiar, n&iacute;vel de alfabetiza&ccedil;&atilde;o, ingest&atilde;o alco&oacute;lica,    n&uacute;mero de parceiros sexuais e profiss&atilde;o de risco. Esta &uacute;ltima    foi considerada como a profiss&atilde;o que implicasse em contato direto ou    potencial com sangue ou outros l&iacute;quidos corporais. O mesmo question&aacute;rio    contemplou tamb&eacute;m outras vari&aacute;veis: realiza&ccedil;&atilde;o pr&eacute;via    de di&aacute;lise peritoneal, n&uacute;mero de procedimentos cir&uacute;rgicos    aos quais o paciente foi submetido e n&uacute;mero de cateteres j&aacute; instalados    no paciente. Informa&ccedil;&otilde;es sobre o per&iacute;odo em que o paciente    j&aacute; havia permanecido sob tratamento hemodial&iacute;tico (tempo de hemodi&aacute;lise),    transfus&otilde;es de sangue e dosagens de alanina aminotransferases foram obtidas    por entrevistas e consultas em prontu&aacute;rios m&eacute;dicos. Amostras de    sangue de todos os pacientes foram colhidas para pesquisa do anti-VHC atrav&eacute;s    de teste ELISA de terceira gera&ccedil;&atilde;o.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000039
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!41
!v701!37
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Para a investiga&ccedil;&atilde;o    de poss&iacute;veis fatores nosocomiais associados ao anti-VHC utilizou-se um    instrumento composto por quest&otilde;es relacionadas aos procedimentos de rotina,    preenchido pelo pr&oacute;prio pesquisador. As informa&ccedil;&otilde;es foram    colhidas com a enfermagem e por observa&ccedil;&atilde;o direta do pesquisador,    que permaneceu em cada cl&iacute;nica por 60 minutos em cada sala, a cada turno,    no momento da pun&ccedil;&atilde;o e liga&ccedil;&atilde;o de todos os pacientes    &agrave;s m&aacute;quinas de di&aacute;lise. Para efeito de an&aacute;lise,    as cl&iacute;nicas foram codificadas e as vari&aacute;veis consideradas foram:</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000040
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!42
!v701!38
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><i>Segrega&ccedil;&atilde;o    em sala de di&aacute;lise:</i> categorizada em <i>sem separa&ccedil;&atilde;o</i>    ou <i>com separa&ccedil;&atilde;o por sala, turno ou m&aacute;quinas</i></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000041
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!43
!v701!39
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><i>Desinfec&ccedil;&atilde;o    de m&aacute;quinas de di&aacute;lise:</i> categorizada em <i>desinfec&ccedil;&atilde;o    ao final do turno, desinfec&ccedil;&atilde;o da m&aacute;quina antes da di&aacute;lise    de paciente anti VHC-negativo ap&oacute;s di&aacute;lise de paciente anti-VHC    positivo</i> e <i>ao final do dia.</i></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000042
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!44
!v701!40
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><i>Falha    no uso ou troca de luvas:</i> considerada quando o profissional n&atilde;o usava    luvas ou n&atilde;o as trocava no manuseio dos pacientes.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000043
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!45
!v701!41
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><i>Segrega&ccedil;&atilde;o    no reprocessamento de dialisadores:</i> categorizada em <i>sem separa&ccedil;&atilde;o</i>    ou <i>algum tipo de separa&ccedil;&atilde;o por ocasi&atilde;o da lavagem dos    dialisadores.</i></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000044
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!46
!v701!42
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><i>Uso de    man&ocirc;metro com isolador de press&atilde;o:</i> referente ao uso de man&ocirc;metro    para aferi&ccedil;&atilde;o da press&atilde;o da linha venosa do sistema extracorp&oacute;reo    acompanhado de instrumento descart&aacute;vel para isol&aacute;-lo e evitar    sua contamina&ccedil;&atilde;o.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000045
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!47
!v701!43
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><i>Preparo    pr&eacute;vio da heparina:</i> considerado quando a dose de heparina era colocada    na seringa para todos os pacientes, antes da pun&ccedil;&atilde;o.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000046
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!48
!v701!44
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2"><b>An&aacute;lise    estat&iacute;stica</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000047
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!49
!v701!45
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">As vari&aacute;veis    cont&iacute;nuas, idade e renda, e as discretas, di&aacute;lise peritoneal e    n&uacute;mero de transfus&otilde;es, foram categorizadas inicialmente segundo    os quart&iacute;s da distribui&ccedil;&atilde;o. Em seguida, os quart&iacute;s    vizinhos que apresentavam preval&ecirc;ncias semelhantes foram agregados de    forma a se obter categorias que melhor discriminassem pacientes com sorologia    positiva ou negativa. As categorias que melhor discriminaram foram aquelas que    apresentaram o menor valor-p no teste do qui-quadrado. As m&eacute;dias foram    comparadas pelo teste <i>t</i> de <i>Student</i>, e um valor-p igual ou menor    do que 0,05 foi considerado significativo. Foi medida a associa&ccedil;&atilde;o,    n&atilde;o ajustada e ajustada, entre fatores de risco e o desfecho pelo <i>odds    ratio</i> e de seu intervalo de confian&ccedil;a, estimados atrav&eacute;s de    regress&atilde;o log&iacute;stica univariada e multivariada, respectivamente.    As associa&ccedil;&otilde;es cujos intervalos de confian&ccedil;a do <i>odds    ratio</i> n&atilde;o inclu&iacute;ram a unidade foram consideradas significativas.    Para isolar o efeito confundidor de vari&aacute;veis, foi usado o modelo de    regress&atilde;o log&iacute;stica multivariada. Nesse modelo, entraram todos    os potenciais fatores de risco individuais e os relacionados &agrave;s cl&iacute;nicas    de hemodi&aacute;lise estudadas, que na an&aacute;lise n&atilde;o ajustada apresentaram    um <i>odds ratio</i> cujo valor-p foi igual ou menor que 0,250. Nas an&aacute;lises    nas quais foi usada regress&atilde;o log&iacute;stica, as categorias das diversas    vari&aacute;veis foram codificadas como 1, 2 ou 3, na seq&uuml;&ecirc;ncia em    que aparecem nas <a href="#tab2">Tabelas 2</a>, <a href="#tab3">3</a> e <a href="#tab4">4</a>.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000048
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!50
!v701!46
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><a name="tab1"></a></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000049
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!51
!v701!47
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000050
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!52
!v701!48
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n2/19777t1.gif"></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000051
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!53
!v701!49
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000052
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!54
!v701!50
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><a name="tab2"></a></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000053
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!55
!v701!51
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000054
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!56
!v701!52
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n2/19777t2.gif"></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000055
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!57
!v701!53
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000056
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!58
!v701!54
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><a name="tab3"></a></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000057
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!59
!v701!55
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000058
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!60
!v701!56
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n2/19777t3.gif"></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000059
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!61
!v701!57
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000060
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!62
!v701!58
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><a name="tab4"></a></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000061
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!63
!v701!59
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000062
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!64
!v701!60
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n2/19777t4.gif" usemap="#Map" border="0">    <map name="Map">     <area shape="rect" coords="405,182,452,195" href="#tab2">     <area shape="rect" coords="462,183,470,191" href="#tab3">   </map> </p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000063
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!65
!v701!61
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000064
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!66
!v701!62
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">O trabalho    foi aprovado pela Comiss&atilde;o de &Eacute;tica e Pesquisa do Hospital Universit&aacute;rio    Walter Cant&iacute;dio da UFC.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000065
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!67
!v701!63
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000066
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!68
!v701!64
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000067
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!69
!v701!65
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Foram avaliados    todos os 752 pacientes que se encontravam em hemodi&aacute;lise nas 12 cl&iacute;nicas    na cidade de Fortaleza (<a href="#tab1">Tabela 1</a>). Desses, 663 foram entrevistados    para coleta de dados sociodemogr&aacute;ficos e cl&iacute;nicos e 83 pacientes    (48 n&atilde;o reagentes; 35 reagentes) participaram apenas do c&aacute;lculo    da preval&ecirc;ncia. N&atilde;o foram, portanto, submetidos &agrave; an&aacute;lise    pelos seguintes motivos: &oacute;bito (N=36), transplante renal (N=17), transfer&ecirc;ncias    para unidades n&atilde;o participantes (N=16), alta (N=8), mudan&ccedil;a de    procedimento dial&iacute;tico (N=5) e recusa (N=1). Al&eacute;m desses, seis    pacientes n&atilde;o foram analisados, devido ao resultado do teste anti-VHC    (ELISA) ter sido caracterizado como "zona cinza". Dos pacientes entrevistados,    60% (397/663) foram do sexo masculino e a idade variou de 10 a 86 anos (m&eacute;dia    de 43,5 anos).</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000068
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!70
!v701!66
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">A preval&ecirc;ncia    m&eacute;dia de pacientes com anticorpos contra o v&iacute;rus da hepatite C    nas diversas cl&iacute;nicas de hemodi&aacute;lise foi de 52% e variou de seis    a 72% (<a href="#tab1">Tabela 1</a>).</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000069
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!71
!v701!67
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">A <a href="#tab2">Tabela    2</a> mostra os dados da medida da associa&ccedil;&atilde;o univariada entre    potenciais fatores de risco individuais e a condi&ccedil;&atilde;o de portador    de anticorpos contra o v&iacute;rus da hepatite C. Dessas vari&aacute;veis,    apenas idade, di&aacute;lise peritoneal, transfus&otilde;es sang&uuml;&iacute;neas    e tempo de hemodi&aacute;lise foram significativamente associadas ao desfecho.    O <i>odds ratio</i> de soropositivos foi significativamente maior entre os pacientes    mais jovens, os que faziam hemodi&aacute;lise h&aacute; mais tempo, os que pelo    menos uma vez haviam se submetido &agrave; di&aacute;lise peritoneal e os que    haviam sido transfundidos.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000070
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!72
!v701!68
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Tamb&eacute;m    foi avaliada a associa&ccedil;&atilde;o univariada entre potenciais fatores    de risco relacionados ao funcionamento das cl&iacute;nicas de hemodi&aacute;lise    e a condi&ccedil;&atilde;o de soropositivo para hepatite C (<a href="#tab3">Tabela    3</a>). Todos os procedimentos relacionados &agrave;s cl&iacute;nicas que foram    analisados se associaram forte e significativamente com a positividade sorol&oacute;gica.    O <i>odds</i> de soropositivos foi significativamente maior entre usu&aacute;rios    de cl&iacute;nicas que apresentaram falha no uso ou troca de luvas, que n&atilde;o    preparavam a heparina previamente e que faziam desinfec&ccedil;&atilde;o de    m&aacute;quinas s&oacute; ao final do dia. Por outro lado, o <i>odds ratio</i>    de soropositivos foi significativamente menor entre os usu&aacute;rios de cl&iacute;nicas    que usavam man&ocirc;metro, que faziam segrega&ccedil;&atilde;o na sala de di&aacute;lise    e no reprocessamento dos dialisadores.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000071
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!73
!v701!69
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Foi medida    a associa&ccedil;&atilde;o ajustada entre cada vari&aacute;vel independente    e a positividade sorol&oacute;gica para hepatite C (<a href="#tab4">Tabela 4</a>).    Depois de ajustado, apenas uso de luvas, preparo da heparina, di&aacute;lise    peritoneal, desinfec&ccedil;&atilde;o de m&aacute;quinas, tempo de hemodi&aacute;lise,    n&uacute;mero de transfus&otilde;es e segrega&ccedil;&atilde;o em sala de di&aacute;lise    foram significativamente associados com a condi&ccedil;&atilde;o de soropositivo.    Observe-se que o fator mais fortemente associado foi uso de luvas. A freq&uuml;&ecirc;ncia    de infec&ccedil;&atilde;o foi significativamente maior em pacientes que fizeram    hemodi&aacute;lise por mais tempo, que se submeteram previamente &agrave; di&aacute;lise    peritoneal e que fizeram alguma transfus&atilde;o sang&uuml;&iacute;nea. E tamb&eacute;m    nos usu&aacute;rios das cl&iacute;nicas onde foram observadas falhas no uso    de luvas, a heparina n&atilde;o era preparada antecipadamente, as m&aacute;quinas    eram desinfetadas s&oacute; ao final do dia e n&atilde;o havia segrega&ccedil;&atilde;o    em sala de di&aacute;lise.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000072
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!74
!v701!70
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000073
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!75
!v701!71
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000074
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!76
!v701!72
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Os resultados    encontrados de alta preval&ecirc;ncia m&eacute;dia de infec&ccedil;&atilde;o    pelo v&iacute;rus da hepatite C (52%) nos pacientes submetidos &agrave; hemodi&aacute;lise,    variando de 6 a 72% nas 12 cl&iacute;nicas de hemodi&aacute;lise, foram semelhantes    aos obtidos em outros estudos no Brasil (65%)<sup>20</sup> e na Venezuela (71%)<sup>18</sup>    e menores do que os observados na Fran&ccedil;a e na B&eacute;lgica.<sup>7,13</sup></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000075
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!77
!v701!73
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">H&aacute;    que se considerar, entretanto, a limita&ccedil;&atilde;o do uso exclusivo do    ELISA, j&aacute; que a positividade para o anti-VHC n&atilde;o implica necessariamente    infec&ccedil;&atilde;o nem em viremia, e a ocorr&ecirc;ncia de infec&ccedil;&atilde;o    pelo v&iacute;rus C deve ser idealmente determinada pela pesquisa do VHC-RNA.    Al&eacute;m disso, quanto a pacientes em hemodi&aacute;lise, freq&uuml;entemente    imunocomprometidos, os anticorpos podem n&atilde;o ser detectados no soro.<sup>14</sup>    A utiliza&ccedil;&atilde;o de ELISA 3, no entanto, apresenta boa sensibilidade    e especificidade (93 a 100% e 77 a 93%, respectivamente);<sup>9</sup> e com    seu uso, tem sido observado encurtamento do intervalo entre a infec&ccedil;&atilde;o    e a detec&ccedil;&atilde;o da soroconvers&atilde;o.<sup>1</sup></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000076
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!78
!v701!74
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">No presente    estudo, observou-se associa&ccedil;&atilde;o entre a positividade de anti-VHC    e a ocorr&ecirc;ncia pr&eacute;via de transfus&otilde;es de sangue, contrariando    a pr&aacute;tica atual de melhor controle dos doadores de sangue e do maior    acesso a eritropoietina recombinante que reduz a necessidade de transfus&otilde;es    sang&uuml;&iacute;neas em pacientes em hemodi&aacute;lise. Esse achado pode    estar relacionado a um certo atraso na introdu&ccedil;&atilde;o de testes sorol&oacute;gicos    para o VHC na triagem de doadores sang&uuml;&iacute;neos, o que, para v&aacute;rios    bancos de sangue brasileiros, s&oacute; ocorreu ap&oacute;s 1993 (portaria 1376).</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000077
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!79
!v701!75
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">No Cear&aacute;,    em um centro de refer&ecirc;ncia estadual, esses exames foram introduzidos na    rotina para sele&ccedil;&atilde;o de doadores por volta de abril de 1994. Em    algumas cl&iacute;nicas, ainda n&atilde;o se pesquisava rotineiramente o anti-VHC    em seus pacientes, por ocasi&atilde;o do presente estudo. Observou-se que 33%    dos pacientes n&atilde;o transfundidos previamente eram reagentes ao anti-VHC.    Tal observa&ccedil;&atilde;o sugere que outros fatores estejam tamb&eacute;m    envolvidos na transmiss&atilde;o de hepatite C nessa popula&ccedil;&atilde;o,    como foi relatado por Jadoul et al<sup>12</sup> (1993) e Corcoran et al <sup>6</sup>    (1994).</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000078
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!80
!v701!76
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Foi verificada    maior positividade de anti-VHC em pacientes que haviam se submetido &agrave;    di&aacute;lise peritoneal. Possivelmente, houve um fator de confus&atilde;o,    j&aacute; que, por algum tempo essa foi a modalidade de tratamento dial&iacute;tico    adotada por algumas cl&iacute;nicas para iniciar o tratamento de seus pacientes.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000079
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!81
!v701!77
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">A m&eacute;dia    de tempo de hemodi&aacute;lise foi maior nos pacientes reagentes para o anti-VHC,    como j&aacute; constatado por outros estudos.<sup>4,5,10</sup> Parece l&oacute;gico    pensar que um paciente h&aacute; mais tempo em tratamento dial&iacute;tico esteja    mais sujeito a acidentes com potencial de contamina&ccedil;&atilde;o e tenha    maior chance de ser transfundido. Por&eacute;m, a associa&ccedil;&atilde;o entre    tempo de di&aacute;lise e positividade para anti-VHC pode n&atilde;o depender    exclusivamente de transfus&otilde;es sangu&iacute;neas.<sup>4</sup></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000080
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!82
!v701!78
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Embora as    rotas exatas dentro da unidade de di&aacute;lise permane&ccedil;am desconhecidas,    h&aacute; evid&ecirc;ncias de transmiss&atilde;o em pacientes que dialisavam    na mesma sala, mesmo que em m&aacute;quinas diferentes.<sup>16</sup> O compartilhamento    de m&aacute;quinas de di&aacute;lise tem sido relacionado &agrave; alta incid&ecirc;ncia    de infec&ccedil;&atilde;o pelo VHC.<sup>8</sup> Assim, tem sido sugerido o controle    da transmiss&atilde;o de hepatite C em sala de di&aacute;lise por meio de separa&ccedil;&atilde;o    por m&aacute;quinas ou de utiliza&ccedil;&atilde;o de salas exclusivas para    pacientes reagentes ao anti-VHC.<sup>2</sup> No presente estudo, a freq&uuml;&ecirc;ncia    de infec&ccedil;&atilde;o foi significativamente maior em pacientes que dialisavam    em cl&iacute;nicas que n&atilde;o faziam segrega&ccedil;&atilde;o em sala de    di&aacute;lise. Outros autores, por&eacute;m, n&atilde;o compartilham da id&eacute;ia    de necessidade de segrega&ccedil;&atilde;o de pacientes reagentes como estrat&eacute;gia    de preven&ccedil;&atilde;o.<sup>11,21</sup></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000081
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!83
!v701!79
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Sampietro    et al<sup>19</sup> (1994) relataram a exist&ecirc;ncia de um risco potencial    de infec&ccedil;&atilde;o cruzada de VHC por flu&iacute;dos de di&aacute;lise;    suas conclus&otilde;es foram baseadas no achado de evid&ecirc;ncias do subtipo    viral desses pacientes em amostras de l&iacute;quidos de di&aacute;lise e ultrafiltrados,    colhidas durante tratamento dial&iacute;tico. No presente estudo, promover a    desinfec&ccedil;&atilde;o das m&aacute;quinas de di&aacute;lise somente no final    do dia associou-se &agrave; maior positividade de anti-VHC, sugerindo a necessidade    de uma maior aten&ccedil;&atilde;o nessa etapa dos procedimentos dentro da unidade    de di&aacute;lise.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000082
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!84
!v701!80
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Outra possibilidade    de contamina&ccedil;&atilde;o reside no momento do reprocessamento de dialisadores.    Como a reutiliza&ccedil;&atilde;o de dialisadores &eacute; regra geral em muitas    unidades de di&aacute;lise, a segrega&ccedil;&atilde;o desses no momento de    seu reprocessamento tem sido levantada. No presente estudo, observou-se na an&aacute;lise    univariada associa&ccedil;&atilde;o entre maior positividade de anti-VHC e pacientes    de cl&iacute;nicas que n&atilde;o segregavam no momento do reprocessamento dos    dialisadores. Por&eacute;m, essa vari&aacute;vel n&atilde;o se manteve no modelo    final da an&aacute;lise de regress&atilde;o log&iacute;stica. Em investiga&ccedil;&atilde;o    conduzida por Pinto dos Santos et al<sup>17</sup> (1996) em 62 unidades de di&aacute;lise    de Portugal, n&atilde;o houve associa&ccedil;&atilde;o com tal pr&aacute;tica.    Houve, por&eacute;m, um menor n&uacute;mero de soroconvers&otilde;es ao anti-VHC    em cl&iacute;nicas que segregavam os dialisadores na sala de reprocessamento;    esse achado, entretanto, n&atilde;o foi ratificado por Jadoul et al<sup>13</sup>    (1998).</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000083
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!85
!v701!81
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">O compartilhamento    parece ser um fator comum na associa&ccedil;&atilde;o com a hepatite C. Pujol    et al<sup>18</sup> (1996) referiram-se ao compartilhamento de equipamentos de    aferi&ccedil;&atilde;o da press&atilde;o venosa, como de risco potencial de    transmiss&atilde;o de hepatite C em cl&iacute;nicas de di&aacute;lise. Sabe-se    que no Pa&iacute;s esse procedimento &eacute; uma constante nas unidades de    di&aacute;lise. Da mesma forma, o compartilhamento do frasco de heparina j&aacute;    foi sugerido como poss&iacute;vel ve&iacute;culo de dissemina&ccedil;&atilde;o    de hepatite C.<sup>10</sup> No presente estudo, o preparo pr&eacute;vio de heparina    na seringa antes de manusear o paciente mostrou associa&ccedil;&atilde;o com    menor preval&ecirc;ncia de anti-VHC.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000084
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!86
!v701!82
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">&Eacute;    reconhecida por muitos a necessidade de estrita observ&acirc;ncia de medidas    de preven&ccedil;&atilde;o e controle de infec&ccedil;&atilde;o pelo VHC.<sup>2,13</sup>    A obedi&ecirc;ncia ao simples preceito de usar e trocar luvas ao manusear pacientes    parece ser uma das medidas mais importantes, tendo em vista que a falha nesse    procedimento foi o fator mais fortemente associado com a positividade sorol&oacute;gica    para hepatite C nesse estudo.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000085
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!87
!v701!83
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000086
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!88
!v701!84
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>AGRADECIMENTOS</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000087
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!89
!v701!85
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Ao Laborat&oacute;rio    Louis Pasteur pelo apoio na realiza&ccedil;&atilde;o dos exames.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000088
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!90
!v701!86
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000089
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!91
!v701!87
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000090
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!92
!v701!88
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">1. Barrera    JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection    of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. <i>Vox    Sang</i> 1995;68:15-8.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!1
!v936!^i0034-8910^y2004^o2
!ID 0000091
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!93
!v701!89
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">2. Blumberg    A, Zehnder D, Burckhardt JJ. Prevention of hepatitis C infection in haemodialysis    units: a prospective study. <i>Nephrol Dial Transplant</i> 1995;10:230-3.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!2
!v936!^i0034-8910^y2004^o2
!ID 0000092
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!94
!v701!90
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">3. Bosmans    JL, Nouwen EJ, Behets G, Gorteman K, Huraib SO, Shaheen FA, et al. Prevalence    and clinical expression of HCV-genotypes in haemodialysis-patients of two geographically    remote countries: Belgium and Saudi-Arabia. <i>Clin Nephrol</i> 1997;36:872-7.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!3
!v936!^i0034-8910^y2004^o2
!ID 0000093
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!95
!v701!91
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">4. Cant&ugrave;    P, Mangano S, Masini M, Limido A, Crovetti G, DeFilippo C. Prevalence of antibodies    against hepatitis C virus in a dialysis unit. <i>Nephron</i> 1992;61:337-8.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!4
!v936!^i0034-8910^y2004^o2
!ID 0000094
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!96
!v701!92
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">5. Cendoroglo    Neto M, Manzano SI, Canziani ME, Silva AE, Cirenza LF, Sesso R de C, et al.    Environmental transmission of hepatitis B and hepatitis C viruses within the    hemodialysis unit. <i>Artif Organs</i> 1995;19:251-5.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!5
!v936!^i0034-8910^y2004^o2
!ID 0000095
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!97
!v701!93
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">6. Corcoran    GD, Brink NS, Millar CG, Garson JA, Waite J, Deaville R, et al. Hepatitis C    virus infection in haemodialysis patients: a clinical and virological study.    <i>J Infect</i> 1994;28:279-85.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!6
!v936!^i0034-8910^y2004^o2
!ID 0000096
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!98
!v701!94
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">7. De Lamballerie    X, Olmer M, Bouchouareb D, Zandotti C, De Micco P. Nosocomial transmission of    hepatitis C virus in haemodialysis patients. <i>J Med Virol</i> 1996;49:296-302.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!7
!v936!^i0034-8910^y2004^o2
!ID 0000097
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!99
!v701!95
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">8. Dimkovic    N, Dragicevic P, Lazic N, Radmilovic A. Further evidence for nosocomial spread    of hepatitis C virus infection in hemodialys is units &#91;letter&#93;. <i>Nephron</i>    1996;74:488.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!8
!v936!^i0034-8910^y2004^o2
!ID 0000098
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!100
!v701!96
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">9. Gerard    C, Vaira D, Maggipinto G, Troonen H, Margraff U, Siquet J, Sondag D. Combination    of serological markers to predict the presence or absence of viremia in HCV-seropositive    blood donors. <i>Vox Sang</i> 1996;71:58-60.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!9
!v936!^i0034-8910^y2004^o2
!ID 0000099
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!101
!v701!97
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">10. Gilli    P, Moretti M, Soffritti S, Marchi N, Malacarne F, Bedani PL, et al. Non-A, non-B    hepatitis and anti-HCV antibodies in dialysis patients. <i>Int J Artif Organs</i>    1990;13:737-41.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!10
!v936!^i0034-8910^y2004^o2
!ID 0000100
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!102
!v701!98
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">11. Gilli    P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus    in dialysis units. <i>Nephron</i> 1995;70:301-6.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!11
!v936!^i0034-8910^y2004^o2
!ID 0000101
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!103
!v701!99
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">12. Jadoul    M, Cornu C, De Strihou CY, The UCL Collaborate Group. Incidence and risk factors    for hepatitis C seroconversion in hemodialysis: a prospective study. <i>Kidney    Int</i> 1993;44:1322-6.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!12
!v936!^i0034-8910^y2004^o2
!ID 0000102
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!104
!v701!100
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">13. Jadoul    M, Cornu C, De Strihou CY, The Universitaires Cliniques St-Luc (UCL) Collaborative    Group. Universal precautions prevent hepatitis C virus transmission: a 54 month    follow-up of the Belgium multicenter study. <i>Kidney Int</i> 1998;59:1022-5.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!13
!v936!^i0034-8910^y2004^o2
!ID 0000103
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!105
!v701!101
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">14. Kurz    P, Kohler H, Meuer S, Hutteroth T, Meyer zum Buschenfelde KH<b>.</b>. Impaired    cellular immune responses in chronic renal failure: evidence for a T cell defect.    <i>Kidney Int</i> 1986;29:1209-14.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!14
!v936!^i0034-8910^y2004^o2
!ID 0000104
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!106
!v701!102
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">15. Naghettini    AV, Daher RR, Martin RM, Doles J, Vanderborght B, Yoshida CF, Rouzere C. Soropreval&ecirc;ncia    do v&iacute;rus da hepatite C na popula&ccedil;&atilde;o em di&aacute;lise de    Goi&acirc;nia, GO. <i>Rev Soc Bras Med Trop</i> 1997;30:113-7.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!15
!v936!^i0034-8910^y2004^o2
!ID 0000105
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!107
!v701!103
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">16. Olmer    M, Bouchouareb D, Zandotti C, De Micco P, Lamballerie X. Transmission of the    hepatitis C virus in na hemodialysis unit: evidence for nosocomial infection.    <i>Clin Nephrol</i> 1996;47:263-70.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!16
!v936!^i0034-8910^y2004^o2
!ID 0000106
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!108
!v701!104
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">17. Pinto    dos Santos J, Loureiro A, Cendoroglo Neto M, Pereira BJG. Impact of dialysis    room and reuse strategies on the incidence of hepatitis C virus infection in    haemodialysis units. <i>Nephrol Dial Transplant</i> 1996;11:2017-22.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!17
!v936!^i0034-8910^y2004^o2
!ID 0000107
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!109
!v701!105
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">18. Pujol    FH, Ponce JG, Lema MG, Capriles F, Devesa M, Sirit F, et al. High incidence    of hepatitis C virus infection in hemodialysis patients in units with high prevalence.    <i>J Clin Microbiol</i> 1996;34:1633-6.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!18
!v936!^i0034-8910^y2004^o2
!ID 0000108
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!110
!v701!106
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">19. Sampietro    M, Graziani G, Badalamenti S, Salvadori S, Caldarelli R, Como G, Fiorelli G.    Detecion of hepatitis C virus in dialysate and in blood ultrafiltrate of HCV-positive    patients. <i>Nephron</i> 1994;68:140.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!19
!v936!^i0034-8910^y2004^o2
!ID 0000109
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!111
!v701!107
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">20. Vanderborght    BOM, Rouzere C, Ginuino CF, Maertens G, Van Heuverswyn H, Yoshida CFT. High    prevalence of hepatitis C infection: a one-year follow-up study. <i>Rev Inst    Med Trop</i> 1995;37:175-9.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!20
!v936!^i0034-8910^y2004^o2
!ID 0000110
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!112
!v701!108
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">21. Zeuzem    S, Scheuermann EH, Waschk D, Lee JH, Blaser C, Franke A, Roth WK<b>.</b> Phylogenetic    analysis of hepatitis C virus isolates from hemodialysis patients. <i>Kidney    Int</i> 1996;49:896-902.</font></p>    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v888!21
!v936!^i0034-8910^y2004^o2
!ID 0000111
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!113
!v701!109
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000112
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!114
!v701!110
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000113
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!115
!v701!111
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back10"></a><b><a href="#top10"><img src="/img/revistas/rsp/v38n2/seta.gif" border="0"></a>    Endere&ccedil;o para correspond&ecirc;ncia    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000114
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!116
!v701!112
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   </b></font><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Maria    Teresa Gon&ccedil;alves de Medeiros    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000115
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!117
!v701!113
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   R. Prof. Dias da Rocha, 2240/1002    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000116
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!118
!v701!114
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   60170-311 Fortaleza, CE, Brasil    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000117
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!119
!v701!115
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   E-mail: <a href="mailto:mtgmce@yahoo.com.br">mtgmce@yahoo.com.br</a></font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000118
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!120
!v701!116
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Recebido    em 18/8/2002    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000119
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!121
!v701!117
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   Reapresentado em 5/8/2003    ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000120
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!122
!v701!118
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<br>   Aprovado em 17/10/2003</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000121
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!123
!v701!119
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000122
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!124
!v701!120
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
!ID 0000123
!v002!S0034-8910(04)03800206
!v004!v38n2
!v700!125
!v701!121
!v702!C:\SciELO\Serial\rsp\v38n2\markup\19777.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">Baseado    em disserta&ccedil;&atilde;o de mestrado apresentada ao Departamento de Medicina    Cl&iacute;nica da Universidade Federal do Cear&aacute;, 1998. Apresentado no    XV Congresso Brasileiro de Hepatologia, Rio de Janeiro, 1999.</font></p>     ^cY
!v705!S
!v706!p
!v708!121
!v709!article
!v880!S0034-89102004000200006
!v882!^v38^n2
!v936!^i0034-8910^y2004^o2
